Royal Fund Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Royal Fund Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-50	Closed	–	–	632
2018 Q2	$0	Buy	+50	New	+$831	﹤0.01%	626

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Royal Fund Management's SGMO Position: Q3 2018 in Review

Royal Fund Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2018, closing a stake of 50 shares.

Royal Fund Management first reported a position in SGMO in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 217 funds tracked by Wall St. Rank hold SGMO as of Q3 2018.

Royal Fund Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2018 after selling out during the quarter.
Royal Fund Management sold 50 SANGAMO THERAPEUTICS INC shares in Q3 2018.
Royal Fund Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2018 and held it in 1 quarter.
Royal Fund Management's SANGAMO THERAPEUTICS INC position peaked at $0 in Q2 2018.
217 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2018.

Based on Royal Fund Management's 13F filing for Q3 2018, filed 7 May 2020.